DiaMedica Therapeutics (DMAC) Accounts Payables (2017 - 2026)

DiaMedica Therapeutics has reported Accounts Payables for 10 years, with the latest figure at $3.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 118.51% year-over-year to $3.3 million; the trailing twelve-month figure through Mar 2026 stood at $3.3 million (up 118.51% YoY), and the FY2025 full-year result was $1.5 million, up 56.91% from the prior year.
• Accounts Payables for Q1 2026 stood at $3.3 million, up from $1.5 million in the prior quarter.
• The five-year high for Accounts Payables was $3.3 million in Q1 2026, with the low at $433000.0 in Q1 2022.
• Historically, Accounts Payables has averaged $1.2 million across 5 years, with a median of $926000.0 in 2023.
• Annual changes were most pronounced in 2023 — Accounts Payables jumped 311.09% — and 2024, when it plunged 59.78%.
• DiaMedica Therapeutics' Accounts Payables stood at $734000.0 in 2022, then advanced by 26.16% to $926000.0 in 2023, then gained by 1.51% to $940000.0 in 2024, then surged by 56.91% to $1.5 million in 2025, then surged by 123.25% to $3.3 million in 2026.
• The last three Accounts Payables figures came in at $3.3 million (Q1 2026), $1.5 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.